Peptide library · Performance & mood
PT-141
Bremelanotide · Vyleesi
FDA approved25%of women gained in desire scores vs 17% on placebo in two phase 3 trials (about 1,250 each)
What it is
A peptide that activates melanocortin receptors in the brain, acting on desire rather than blood flow.
Why researchers are interested
- FDA approved in 2019 for low sexual desire in premenopausal women.
- Also reduced distress about low desire in the RECONNECT trials.
Good to know
- Prescription medicine.
- Nausea in about 40% of users; temporary blood pressure rise.
Evidence level: 4 of 5
Sources
Obstet Gynecol 2019 (RECONNECT); FDA approval, Jun 2019
Get the weekly research brief
New trials, FDA decisions and plain language breakdowns every Thursday. Free, plus the GLP-1 cheat sheet when you join.
Join freeRelated profiles
Educational content only. Not medical advice. Last reviewed 2026-10-17.